Clinical Trial Update: Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating matuzumab in combination with epirubicin, cisplatin, and capecitabine (ECX) for esophago-gastric cancer; study complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Epireubicin/cisplatin/capecitabine (ECX)
• matuzumab (matuzumab)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-11-02